Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cevostamab - Genentech

Next Previous
Drug Profile

Cevostamab - Genentech

Alternative Names: BFCR-4350A; RG 6160; RO-7187797

Latest Information Update: 24 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Genentech; Roche
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fv fragments; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 21 Sep 2026 Canadian Myeloma Research Group plans a phase I MAPLE trial for Multiple Myeloma (Second-line therapy or greater, Combination therapy, In adult, In the elderly) in Canada (NCT07831122)
  • 04 Sep 2026 Phase-II clinical trials in Multiple myeloma (Second-line therapy or greater, Combination therapy) in Germany (IV) (NCT07825064) (CTIS2026-525736-42-00)
  • 03 Aug 2026 Roche plans a phase II trial for Multiple myeloma (Second-line therapy or greater; Combination therapy) in Germany (IV, Infusion), in October 2026 (CTIS2026-525736-42-00)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top